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Introduction
In endocrine and neuroendocrine cells, bioactive molecules are 
packaged into nascent vesicles called immature secretory gran-
ules (ISGs), which bud from the TGN and are destined for 
  regulated secretion (Arvan and Castle, 1998; Tooze, 1998). ISGs 
undergo a series of maturation steps, including acidifi  cation of 
the granule lumen, prohormone processing (Orci et al., 1987; 
Moore et al., 2002), AP-1–dependent removal of proteins  (Dittie 
et al., 1997; Kuliawat et al., 1997; Klumperman et al., 1998), 
and ISG–ISG homotypic fusion (Urbé et al., 1998), to become 
mature secretory granules (MSGs). MSGs, which are also called 
large dense core vesicles, accumulate in cells until they undergo 
fusion with the plasma membrane by regulated exocytosis.
An in vitro fusion assay that reconstitutes ISG–ISG fu-
sion has revealed that ISG homotypic fusion is dependent on 
NSF and α-SNAP (Urbé et al., 1998) and on the SNARE pro-
tein syntaxin 6 (Stx6), but not on Stx1 or SNAP-25 (Wendler 
et al., 2001). SNAREs are essential components of membrane 
fusion, but whether they are suffi  cient for fusion and/or  ensuring 
targeting specifi  city remains under debate. Additional proteins, 
including the Rabs (Zerial and McBride, 2001) and the synapto-
tagmins (Syts; Chapman, 2002), may coordinate and regulate 
vesicle traffi  cking and fusion.
The Syts are a family of proteins characterized by a short 
lumenal NH2 terminus, one transmembrane region, and tandem 
C2A and C2B domains (Perin et al., 1991; Bai and Chapman, 
2004). Currently, it is thought that Syts participate in the regula-
tion of various steps during membrane fusion, primarily at the 
plasma membrane. Syt I, which was the fi  rst isoform identifi  ed 
(Matthew et al., 1981), is involved in calcium-dependent exo-
cytosis (Fernandez-Chacon et al., 2001) and functions as the 
  calcium sensor that stabilizes the opening of the fusion pore at 
the fi  nal steps of fusion (Wang et al., 2001), at the docking step 
(Chieregatti et al., 2002, 2004), and during vesicle recycling from 
the plasma membrane (Nicholson-Tomishima and Ryan, 2004). 
Syt I binds to the SNARE proteins Stx1 and SNAP-25 (Bennett 
et al., 1992; Schiavo et al., 1997), and this binding is thought to 
be important for the function of Syt I in membrane fusion.
A genomic analysis has identifi   ed 16 Syt isoforms in 
mammals (Craxton, 2004), so that, like SNAREs or Rabs, Syts 
constitute a large family of proteins, suggesting that they regu-
late multiple membrane events. In support of this, although still 
controversial, a differential distribution of Syt I, III, IV, and VII 
has been reported in neuroendocrine cells (Ibata et al., 2000; 
Sugita et al., 2001; Fukuda et al., 2004). Moreover, a recent 
study in Drosophila melanogaster showed that Syt isoforms 
  localize to nonoverlapping subcellular compartments (Adolfsen 
et al., 2004).
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n neuroendocrine PC12 cells, immature secretory 
  granules (ISGs) mature through homotypic fusion and 
membrane remodeling. We present evidence that the 
ISG-localized synaptotagmin IV (Syt IV) is involved in ISG 
maturation. Using an in vitro homotypic fusion assay, we 
show that the cytoplasmic domain (CD) of Syt IV, but not 
of Syt I, VII, or IX, inhibits ISG homotypic fusion. More-
over, Syt IV CD binds speciﬁ  cally to ISGs and not to   mature 
secretory granules (MSGs), and Syt IV binds to syntaxin 6, 
a SNARE protein that is involved in ISG maturation. 
ISG homotypic fusion was inhibited in vivo by small inter-
fering RNA–mediated depletion of Syt IV. Furthermore, 
the Syt IV CD, as well as Syt IV depletion, reduces secre-
togranin II (SgII) processing by prohormone convertase 2 
(PC2). PC2 is found mostly in the proform, suggesting that 
activation of PC2 is also inhibited. Granule formation, 
and the sorting of SgII and PC2 from the trans-Golgi 
  network into ISGs and MSGs, however, is not affected. 
We conclude that Syt IV is an essential component for secre-
tory granule maturation.
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Syt IV (Hilbush and Morgan, 1994) was characterized as 
an immediate early gene induced by depolarization in PC12 
cells and rat brain (Vician et al., 1995). Syt IV knockout mice 
exhibit abnormalities in motor performance, suggesting a role 
in synaptic plasticity (Ferguson et al., 2000). The function of 
Syt IV in   vesicular traffi  cking, however, remains unclear. Over-
expressed Syt IV is sorted to MSGs upon NGF differentiation 
or forskolin treatment of PC12 cells, and is involved in the regu-
lation of exocytosis (Fukuda et al., 2003; Wang et al., 2003; 
  Fukuda and Yamamoto, 2004; Machado et al., 2004). Different 
studies have found contradictory localizations; Syt IV has been 
shown to   colocalize with Syt I on synaptic vesicles and MSGs 
in PC12 cells (Ferguson et al., 1999), whereas others demon-
strated that Syt IV has a juxtanuclear distribution (Ibata et al., 
2000), is   localized on ISGs and not MSGs in PC12 and AtT20 
cells, and does not colocalize with Syt I (Eaton et al., 2000; 
Ibata et al., 2002; Fukuda et al., 2003).
The function of endogenous Syt IV in relation to its lo-
calization in nondifferentiated neuroendocrine cells has never 
been studied. In PC12 cells, Syt IV is found on ISGs, but not 
on MSGs, and we have investigated whether Syt IV could be 
involved in ISG–ISG homotypic fusion before its removal from 
MSGs. We show that the cytoplasmic domain (CD) of Syt IV, 
but not of Syt I, VII, or IX, inhibits ISG–ISG homotypic fusion 
in an in vitro homotypic fusion assay, and that this   domain is 
recruited specifi  cally to ISG membranes. The role of Syt IV in 
ISG homotypic fusion was confi  rmed in vivo after siRNA-
  mediated depletion of Syt IV. We also fi  nd that Syt IV binds 
Stx6, and that Syt IV interacts with Stx6 via both the C2A and 
C2B domains. We show in the in vitro homotypic   fusion assay 
that addition of the Syt IV CD, together with an anti-Stx6 anti-
body, leads to an additive inhibition of fusion, and we specu-
late that Syt IV and Stx6 are involved in regulating different 
stages of ISG homotypic fusion. Furthermore,  using the dominant-
negative Syt IV CD, and by the reduction of Syt IV levels using 
siRNA, we demonstrate in vivo a reduction of secretogranin II 
(SgII) processing by prohormone convertase 2 (PC2). Finally, 
we show that in cells transfected with the dominant-negative 
Syt IV CD, PC2 is mostly in the unprocessed/inactive proform. 
Collectively, our data provide the fi  rst direct evidence that 
Syt IV is involved in an intracellular membrane fusion event 
and in the regulation of secretory granule maturation in neuro-
endocrine cells.
Results
Syt IV is localized to ISGs, and not MSGs, 
in PC12 cells
We fi rst determined the distribution of Syt IV using subcellu-
lar fractionation techniques to isolate and separate ISGs and 
MSGs. PC12 cells were [
35S]sulfate-labeled either for short 
periods (5 min pulse and 15 min chase) to label ISGs or over-
night (1 h pulse, overnight chase) to label MSGs (Tooze et al., 
1991). The postnuclear supernatant (PNS) from labeled cells 
was subjected to continuous velocity sucrose gradient frac-
tionation and analysis. Syt IV was found mainly in the light 
ISG-containing fractions, as well as in Golgi-containing frac-
tions at the bottom of the gradient (Fig. 1 A, top), in contrast 
to Syt I, which localizes mainly to MSGs and synaptic-like 
microvesicles (Perin et al., 1991) and is found mainly in the 
slightly heavier fractions (Fig. 1 A, bottom).  The ISG and MSG 
fractions were further separated on discontinuous equilibrium 
sucrose gradients (Fig. 1, B and C). Syt IV was in the ISG-
containing fractions, together with [
35S]sulfate-labeled SgII 
and Stx6, which were previously shown to be on ISGs and not 
MSGs (Fig. 1 B; Wendler et al., 2001). However, Syt IV was 
not found in the MSG fractions, which were identifi  ed by the 
presence of [
35S]sulfate-labeled SgII together with Syt I (Fig. 
1 C, bottom). By indirect immunofl  uorescence in PC12 cells, 
Syt IV displayed a juxtanuclear distribution (Ibata et al., 2000) 
and colocalized with Stx6 (Fig. S1 A, available at http://www.
jcb.org/cgi/content/full/jcb.200506163/DC1).
To confi  rm that Syt IV is not on MSGs, we used a PC12 
cell line stably expressing PC2 (PC12/PC2 cells; Dittie and 
Tooze, 1995). In PC12/PC2 cells, PC2 cleaves SgII at several 
dibasic residues and produces a product of 18 kD (p18), which 
accumulates in MSGs and can be detected using an antibody 
that recognizes only p18, but not full-length or partially pro-
cessed SgII. As shown in Fig. S1 B, a nonoverlapping distribu-
tion of Syt IV and p18 or Syt I was observed in PC12/PC2 cells. 
Figure 1.  Syt IV is found on the Golgi and ISGs in PC12 cells. (A) Frac-
tions from a 0.3–1.2 M continuous velocity sucrose gradient loaded with 
a PNS from PC12 cells were collected and analyzed with anti–Syt IV (top) 
and Syt I (bottom) antibodies. Alternatively, PC12 cells were labeled with 
[
35S]sulfate for 5 min and chased for 15 min (B) or labeled for 1 h and 
chased O/N (C) to label ISGs or MSGs, respectively, and then subjected 
to velocity centrifugation. (B and C) Fractions 1–4 (B) or 4–6 (C) from the 
velocity gradients were further separated on a 0.8–1.6 M discontinuous 
equilibrium sucrose gradient and analyzed. (B and C, top) Autoradio-
gram showing [
35S]sulfate-labeled CgB (B) and SgII (B and C). (B and C, 
bottom) Western blot analysis using anti–Syt IV and anti-Stx6 antibodies 
(B) or anti–Syt IV and anti–Syt I antibodies (C). In B, the diffuse band 
  between 120 and 90 kD is a heparan sulfate proteoglycan (Tooze and 
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We conclude, in agreement with others (Eaton et al., 2000; 
  Fukuda et al., 2003), that Syt IV is localized to ISGs, and not 
to MSGs, in PC12 cells.
Syt IV CD, but not Syt I, VII, or IX, 
inhibits in vitro ISG homotypic fusion
Because Syt IV is localized on ISGs, but not on MSGs, we 
  hypothesized that it could play a role in granule maturation. 
In PC12 cells, ISGs undergo homotypic fusion during matura-
tion, followed by excess membrane removal, most likely via 
AP-1–containing clathrin-coated vesicles. To test whether Syt IV 
is involved in the maturation of ISGs, we used an in vitro fusion 
assay that reconstitutes ISG homotypic fusion (Urbé et al., 
1998). Addition of increasing amounts of the purifi  ed recombi-
nant Syt IV CD into the complete fusion reaction resulted in a 
dose-dependent inhibition of ISG homotypic fusion by  40% 
(Fig. 2).  Addition of the denatured CD had no effect on ISG–
ISG fusion (unpublished data). In addition to Syt IV, Syt I, VII, 
and IX are the most abundant isoforms in PC12 cells, with Syt 
VII found at lower levels (Zhang et al., 2002; Wang et al., 2005). 
Furthermore, Syt I and IX are localized on MSGs and are 
  involved in the regulation of calcium-dependent exocytosis in 
these cells (Elferink et al., 1993; Fukuda, 2002). Syt VII was 
  localized either to the plasma membrane (Sugita et al., 2001) or 
to large dense core vesicles (Fukuda et al., 2004), and was also 
shown to be involved in the regulation of calcium-triggered 
  fusion with the plasma membrane (Sugita et al., 2001; Fukuda 
et al., 2004; Wang et al., 2005).
We asked if ISG homotypic fusion could be regulated by 
the other Syt isoforms present in PC12 cells. Purifi  ed Syt I, VII, 
and IX CDs, which were previously shown to inhibit exocytosis 
(Earles et al., 2001; Tucker et al., 2003), had no effect on ISG 
homotypic fusion (Fig. 2). We conclude that the inhibition 
of ISG–ISG fusion is specifi  c for Syt IV and does not involve 
Syt I, VII, or IX.
Many membrane fusion events, including the fusion of 
secretory granules with the plasma membrane (Heinemann 
et al., 1994), require calcium. However, it has never been deter-
mined whether ISG homotypic fusion is calcium dependent. 
We found that the addition of increasing amounts of 1,2-bis
(o-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid (BAPTA) 
into the complete ISG–ISG fusion assay resulted in a dose-
  dependent inhibition of fusion of up to 95% (Fig. S2, available 
at http://www.jcb.org/cgi/content/full/jcb.200506163/DC1). 
The addition of equimolar BAPTA and calcium partially re-
stored ISG–ISG fusion, and the addition of BAPTA alone after 
the fusion reaction had little effect. These results clearly dem-
onstrate that ISG homotypic fusion is dependent on calcium. 
It was assumed that rat Syt IV is a calcium sensor because of the 
presence of the predicted calcium-binding residues in the C2B 
domain (Wang et al., 2003). However, a recent crystal structure 
revealed that changes in the orientation of the calcium-binding 
residues render the rat Syt IV C2B domain unlikely to bind 
  calcium (Dai et al., 2004). Thus, it is likely that Syt IV is not the 
calcium sensor protein regulating ISG–ISG fusion and that an-
other calcium-binding protein is regulating this process. Further 
work is required to clarify and confi  rm this speculation.
The Syt IV CD is recruited speciﬁ  cally 
to ISG membranes via protein components
Because the Syt IV CD was able to inhibit ISG homotypic 
  fusion, we asked whether the site of inhibition resides on these 
membranes using an in vitro ISG-binding assay, which we have 
used to demonstrate ADP-ribosylation factor 1 and AP-1 bind-
ing to ISG membranes (Dittie et al., 1996; Austin et al., 2000). 
The addition of increasing amounts of Syt IV CD to ISGs 
showed a dose-dependent binding (Fig. 3 A), demonstrating 
that ISG membranes contain binding sites for Syt IV. No recom-
binant protein was detected in the pellet in the absence of ISGs, 
establishing that the binding is not a result of nonspecifi  c aggre-
gation of the protein. To test whether the binding is specifi  c, 
7 nM Syt IV CD was added to 50 μl ISGs or MSGs. The Syt IV 
CD bound to ISG, whereas no binding to MSG was observed 
(Fig. 3 B). In contrast, Syt I CD was able to bind both ISG and 
MSG membranes (Fig. 3 B). There was more binding of the Syt I 
CD to ISGs compared with MSGs, which might be attributed 
to the presence of synaptophysin-positive synaptic-like micro-
vesicles in the ISG fraction (Regnier-Vigouroux et al., 1991). 
These results show that Syt IV binds specifi  cally to components 
that are present on ISGs and absent from MSGs, and further 
suggest that the site of inhibition of ISG–ISG fusion by the Syt IV 
CD is on the ISG membrane.
In liposome-binding assays, some Syts such as Syt I and IX, 
but not Syt IV, are able to bind phospholipids via their
C2 domains in a calcium–dependent manner (Hui et al., 2005). 
However, others showed that Syt IV is able to bind liposomes 
containing only negatively charged phospholipids (Fukuda 
et al., 1996). Although we do not know the lipid composition of 
ISG membranes, it is unlikely that they are composed solely of 
negatively charged phospholipids. To determine whether the re-
cruitment of the Syt IV CD is mediated through protein or lipid 
components, we repeated the binding assays after pretreatment 
Figure 2.  The CDs of Syt IV, but not of Syt I, VII, or IX, inhibit ISG homo-
typic fusion. An ISG homotypic fusion assay was performed as previously 
described by Urbé et al. (1998), which measures fusion by the production 
of p18 from [
35S]sulfate-labeled SgII. The complete fusion reaction contains 
PC2 ISGs, PC12 [
35S]sulfate-labeled PNS, and ATP. Syt IV (circle), Syt I 
  (inverted triangle), Syt VII (triangle), or Syt IX (diamond) CDs were added 
at the indicated concentrations, on ice, and then the fusion assay was per-
formed. After subtraction of the background from PC2-ISG minus reactions, 
the fusion was assayed by quantifying the amount of p18 produced and is 
presented as a percentage of the complete fusion reaction. The data repre-
sent the mean of three experiments done in duplicate. Error bars are the 
SEM. The addition of more Syt IV CD did not increase the inhibition   beyond 
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of ISG membranes with increasing amounts of trypsin, followed 
by the addition of trypsin inhibitor. We found that the recruit-
ment of Syt IV CD to ISGs is trypsin sensitive (Fig. 3 C). When 
trypsin inhibitor was added before trypsin, the recruitment to 
ISG membranes of Syt IV was not reduced. The lumenal pro-
tein SgII was not degraded by the trypsin treatment (Fig. 3 C, 
bottom), demonstrating that ISGs remained intact during the 
  assay. Although we cannot exclude the activation of phospho-
lipases by trypsin, which would alter the composition of the 
membrane, our results, together with the recent confi  rmation of 
Syt IV’s inability to bind phospholipids (Hui et al., 2005), sug-
gest that protein components on ISGs are necessary for the 
  recruitment of the Syt IV CD.
Syt IV interacts with the SNARE Stx6
Our results suggest that the Syt IV CD is able to inhibit ISG–
ISG homotypic fusion via recruitment to ISGs. Syts bind to 
SNARE proteins to regulate membrane fusion. Syt I, for exam-
ple, is able to bind Stx1 and SNAP-25 (Bai and Chapman, 
2004), and it is thought that this binding is an important facet 
of the ability of Syt I to regulate exocytosis (Earles et al., 2001). 
We hypothesized that Syt IV may be part of a protein complex 
involved in an ISG homotypic fusion that contains Stx6, so we 
looked for an interaction between Stx6 and Syt IV. In GST 
pull-down assays from transfected human embryonic kidney 
293 (HEK293) cell lysates, we found that myc-Stx6 binds to 
GST-Syt IV CD and not to GST alone (Fig. 4 A). Furthermore, 
we were able to coimmunoprecipitate Syt IV with Stx6 from 
Figure 3.  Syt IV CD is recruited to ISG membranes. (A) 20 nM of Syt IV 
CD was incubated for 30 min at 37°C with or without 50 μl PC12 ISGs, 
or increasing amounts of Syt IV CD were added to 50 μl ISGs in fusion 
buffer with ATP. The amount of Syt IV bound to ISG membranes was deter-
mined by immunoblotting with anti–Syt IV antibody and quantiﬁ  ed using 
ImageJ software. The data are the mean of three experiments done in du-
plicate. Error bars are the SEM. (B) 7 nM Syt IV or Syt I CDs were preincu-
bated with 50 μl ISGs or MSGs in fusion buffer with ATP. The amount 
of Syt IV or Syt I bound was determined as described in Materials and 
methods. (C) 50 μl ISGs were preincubated with increasing amounts of trypsin. 
Trypsin inhibitor was added before (*) or after the preincubation. Binding 
reactions including 18 nM Syt IV CD were performed as described in 
  Materials and methods. The amount of Syt IV bound to ISGs was detected 
with an anti–Syt IV antibody (top). The blot was stripped and reprobed 
with an anti-SgII antibody (bottom).
Figure 4.  Syt IV interacts with Stx6. (A) Cell lysates from HEK cells trans-
fected with myc-Stx6 were incubated with GST-Syt IV CD or GST bound to 
glutathione beads. (B) PC12 cells were lysed in TNTE buffer and incubated 
with 5 or 10 μg of anti-Stx6 antibody overnight at 4°C, and subsequently 
bound to protein G beads. Immunoprecipitates and 2.5% of the input were 
analyzed by immunoblotting with anti–Syt IV antibody. (C) Direct binding 
of Stx6 to Syt IV in vitro. 3 μg of GST-Syt IV CD bound to glutathione beads 
was incubated with the indicated amounts of the Stx6 CD in binding buffer 
overnight, and bound protein was analyzed by immunoblotting with anti-
Stx6 antibody 3D10. (D) The Syt IV–Stx6 interaction in vitro is independent 
of Ca
2+. Binding assays were performed as in C, using 1 μM Stx6 CD, 
supplemented with either 1 mM CaCl2 or 2 mM EGTA.SYT IV REGULATES ISG MATURATION • AHRAS ET AL. 245
PC12 cells, showing that endogenous Syt IV and Stx6 interact 
(Fig. 4 B). Next, to test whether Syt IV binds directly to Stx6, 
GST-Syt IV CD was incubated with increasing amounts of re-
combinant Stx6 CD. Syt IV CD was able to interact directly 
with Stx6 in a dose-dependent manner (Fig. 4 C). Together, 
these results suggest that Syt IV and Stx6 are part of the same 
protein complex.
Previous data showed that Syt VIII, which is another iso-
form that was initially characterized as a calcium binding–
 defi  cient Syt, was able to interact with Stx2 in a calcium-dependent 
manner (Hutt et al., 2005). Therefore, we tested the possibility 
that Syt IV, which was also thought not to bind calcium (Dai 
et al., 2004), binding to Stx6 might be promoted by calcium. 
We tested the binding of GST-Syt IV CD with recombinant Stx6 
CD in the presence of either 2 mM EGTA or 1 mM Ca
2+. Syt IV 
binding to Stx6 was similar in all conditions (Fig. 4 D), suggest-
ing that the interaction is calcium independent.
Furthermore, to investigate which Syt IV domain is re-
quired for binding to Stx6, we performed coimmunoprecipita-
tion experiments with lysates prepared from HEK293 cells 
expressing myc-Stx6 and either HA-Syt IV-C2A, HA-Syt IV-
C2B, or HA-Syt IV CD. HA-Syt IV CD could coimmunopre-
cipitate myc-Stx6 (Fig. 5, A and B), as could both HA-Syt IV-
C2A and HA-Syt IV-C2B domains (Fig. 5 C). Similarly, 
myc-Stx6 could coimmunoprecipitate both HA-Syt IV-C2A 
and HA-Syt IV-C2B domains (Fig. 5 D). This result demon-
strates that both domains are involved in the binding to Stx6. 
The binding effi  ciency of the individual Syt IV domains to myc-
Stx6 was lower compared with the binding effi  ciency of the 
complete CD, suggesting that the C2A and C2B domains coop-
erate to bind Stx6, as is the case for Syt I binding to SNAREs 
(Bai and Chapman, 2004).
Syt IV and Stx6 inhibition of ISG 
homotypic fusion is additive
After our fi  ndings that Syt IV binds Stx6 and that both are in-
volved in ISG–ISG fusion, we investigated the effect of inhibi-
tory reagents in the homotypic fusion assay. Our previous 
results (Wendler et al., 2001), along with the results in Fig. 2, 
show that the inhibition by each reagent individually was at 
most 50%. Combining reagents in the fusion assay increased 
inhibition of ISG homotypic fusion to 80% (Fig. 6 A). 
Figure 5.  Syt IV interacts with Stx6 via both C2A and C2B domains.
(A and B) HEK293 cells were cotransfected with HA-Syt IV CD and myc-
Stx6. Lysates from untransfected and transfected cells were used for immuno-
precipitation with anti-HA (+) or beads alone (−; A) and with anti-myc 
antibody or beads alone (B). Immunoprecipitates and 10% of total input 
were analyzed with anti-myc (A) or anti-HA (B) antibodies by immuno-
blotting. (C and D) Lysates from HEK293 cells cotransfected with either 
HA-Syt IV C2A or C2B domain and myc-Stx6 were subjected to immuno-
precipitation with either anti-myc antibody or beads alone (C), blotted 
with anti-HA antibody or anti-HA antibody or beads alone (D), and then 
blotted with anti-myc antibody. Figure 6.  Syt IV CD and Stx6 antibody have an additive inhibitory effect 
on ISG homotypic fusion. (A) A complete fusion reaction was incubated 
with 9 μM Syt IV CD and 10 μg anti-Stx6 antibody, or Syt IV CD and anti-
Stx6 antibody. Fusion reactions were performed, treated, and analyzed 
(see Materials and methods). p18 signals were quantiﬁ  ed using ImageJ 
analysis software, and the background signal measured in the absence of 
PC2 ISGs was subtracted. The data is the mean of three independent ex-
periments done in duplicate. Error bars are the SEM. (B) A complete fusion 
reaction was incubated with 9 μM Syt IV CD, 10 μg anti-Stx6 antibody, 
9 μM Syt I CD, 10 μg anti-Stx1 antibody, Syt IV CD and anti-Stx1 anti-
body, 9 μM Syt I CD and 10 μg anti-Stx6 antibody, or 10 μg anti-Stx6 an-
tibody and 9 μM Syt IV CD. p18 signals were quantiﬁ  ed as described in A.JCB • VOLUME 173 • NUMBER 2 • 2006  246
The  addition of anti-Stx1 antibody, which was previously shown to 
have no effect on fusion, combined with the Syt IV CD, had no 
additional effect. Likewise, the addition of anti-Stx6 antibody 
with Syt I CD had no additional effect, demonstrating that the 
additive inhibitory effect is specifi  c for Syt IV and Stx6 (Fig. 6 B). 
Preincubation of the fusion reaction with anti-Stx6 antibody for 
30 min on ice before the addition of Syt IV CD (and vice versa) 
resulted in the same degree of inhibition of ISG homotypic fu-
sion as when the two components were added simultaneously 
(unpublished data).
Syt IV is required for ISG fusion 
and SgII processing in vivo
To test directly the role of Syt IV in ISG maturation in vivo, and 
in homotypic fusion in particular, we depleted Syt IV from 
PC12/PC2 cells using siRNA and asked if ISG–ISG fusion was 
affected. Using a Syt IV–specifi  c antibody, we observed a re-
duction of up to 95% in Syt IV levels in >80% of the siRNA-
treated PC12/PC2 cells by both indirect immunofl  uorescence 
and immunoblotting, whereas Syt I distribution and levels 
  remained unchanged in the absence of Syt IV (Fig. 7, A and B). 
ISG maturation in vivo is characterized by an increase in the 
size of ISGs on velocity-controlled sucrose gradients that oc-
curs between 15 and 75 min after ISGs are formed from the 
TGN (Tooze et al., 1991). This increase in size refl  ects ISG–ISG 
fusion (Urbé et al., 1998). Therefore, we tested whether Syt IV 
was required for the fusion of ISGs in vivo by assaying for 
an increase in the size of ISGs (in particular the [
35S]sulfate-
labeled granule protein SgII in the ISGs) during a chase of up to 
60 min (Fig. 7 C). As shown in Fig. 7 (D and E), depletion of 
Syt IV resulted in an inhibition of the time-dependent size 
  increase of ISGs.
During secretory granule maturation in endocrine or neu-
roendocrine cells, SgII, like many other secretory granule pro-
teins and prohormones, is processed by PC2 in a pH-dependent 
reaction, which starts in the TGN and continues into the MSG 
(Urbé et al., 1997). We investigated whether PC2 processing of 
SgII was affected by the inhibition of fusion because of the ab-
sence of Syt IV by observing the processing of newly synthe-
sized SgII in Syt IV siRNA-treated PC12/PC2 cells. In PC12/PC2 
cells, after exit from the TGN and during the chase period, SgII 
is processed at several sites by PC2 to generate 38-, 28-, and 
18-kD (p18) products (Dittie and Tooze, 1995). This processing 
can be detected after a short pulse of [
35S]sulfate to label the 
TGN pool, followed by a chase with excess sulfate. In the ab-
sence of Syt IV, we observe reduced processing of the full-
length 86-kD SgII (Fig. 8 A).  The extent of this inhibition was 
determined from the ratio of p86 to p38 (Fig. 8 B). Before 
30 min of chase, very little processing is detectable in this pulse-
chase analysis, whereas maximum inhibition occurs between 
Figure 7.  siRNA-mediated depletion of Syt IV 
results in inhibition of ISG fusion. PC12/PC2 
cells were either transfected with 50 nM Syt IV 
siRNA or mock-transfected with transfection re-
agents alone. (A) 72 h after transfection, cells 
were labeled with anti–Syt IV (green) or anti–
Syt I (blue). Images were taken using a Zeiss 
LSM510 confocal microscope. Bars, 20 μm. 
(B) 10 μg mock- or siRNA-treated cell lysates 
were solubilized and analyzed with anti–Syt 
IV and anti–Syt I antibodies. (C) Scheme for 
the pulse-chase labeling protocol and analysis 
of ISG size used in D and E, as well as in 
Fig. 8 A (Tooze et al., 1991). (D) 72 h after mock 
or Syt IV siRNA treatment, PC12 cells were 
  labeled, harvested, and analyzed by velocity-
controlled sucrose gradient fractionation. Frac-
tions 1–12 were analyzed from gradients 
loaded with PNS prepared from mock- or 
siRNA-treated cells after a 60-min chase. In mock-
treated cells, SgII is found in ISGs sedimenting 
in fractions 2–6, whereas in Syt IV siRNA-
treated cells ISGs containing SgII are found 
in fractions 1–4. (E) Quantitation of the posi-
tion of SgII in fractions 1–6 from velocity gradi-
ents loaded with cells treated as in D and 
chased for 30 and 60 min. The average of two 
experiments is shown.SYT IV REGULATES ISG MATURATION • AHRAS ET AL. 247
45 and 60 min of chase, when in the mock-treated cells the rate 
of processing is highest. We conclude from these results that in 
PC12 cells Syt IV is required for fusion of ISGs and effi  cient 
processing of SgII.
The Syt IV CD inhibits SgII processing 
and maturation of PC2
Next, we investigated the role of Syt IV in ISG maturation in vivo 
using the Syt IV CD, in particular, to determine if the reduction 
in SgII processing was a direct result of an inhibition of matura-
tion or an alteration in PC2 sorting. As mentioned in the previous 
section, SgII in PC12/PC2 cells is processed to p18. p18 can be 
detected with an anti-p18 antibody recognizing only p18 and not 
larger SgII precursors. We used wild-type PC12 cells transfected 
with PC2 to eliminate the background signal from p18 stored in 
MSGs existing before addition of the dominant-negative HA-Syt IV 
CD, and asked if the appearance and accumulation of p18 in 
MSGs was affected by expression of the Syt IV CD. Transfection 
of the HA-Syt IV CD together with PC2 into PC12 cells resulted 
in an inhibition of p18 accumulation, whereas transfection of 
the Syt I CD together with PC2 or of PC2 alone, had no effect on 
p18 appearance (Fig. 9 A).  Quantifi  cation of the intensity of the 
p18 signal in an equivalent number of cells cotransfected with 
HA-Syt IV CD and PC2 revealed a threefold decrease in p18 in 
these cells compared with cells transfected with PC2 alone or 
with Syt I CD and PC2 (Fig. 9 B).
Because we observed a decrease in SgII processing using 
the Syt IV CD, we tested whether excess full-length Syt IV in-
creased p18 levels. Using FACS analysis, there was no differ-
ence in p18 in untransfected PC12/PC2 cells or cells transfected 
with full-length Syt IV or I (unpublished data). We speculate that 
the lack of a stimulatory effect on maturation by excess Syt IV 
may be attributable to a limitation of Syt IV effectors that are 
necessary for granule maturation, and which may also need to be 
overexpressed. We have also tested whether the effect of Syt IV 
on p18 production is calcium-dependent by mutating the fi  rst 
and second aspartate residues within the C2B domain to aspara-
gine (D318/324N); these mutations were previously shown to 
block glutamate release in glial cells (Zhang et al., 2004). 
  Expression of this double mutant or full-length Syt IV together 
with PC2 did not affect p18 production in PC12 cells (unpub-
lished data), suggesting that the dominant-negative   effect 
on SgII processing observed with HA Syt IV CD is independent 
of calcium.
PC2 is found as a 75-kD precursor in the TGN, which is 
then endoproteolytically cleaved to the 65-kD mature form in a 
pH-dependent manner (Zhou et al., 1999). PC2 activation de-
pends on propeptide cleavage in the presence of bound 7B2, 
which is a member of the granin family shown to behave as a 
chaperone for pro-PC2 (Mbikay et al., 2001). We asked if inhi-
bition of SgII processing by the dominant-negative Syt IV CD 
might be a result of failure to activate PC2. Therefore, we looked 
at PC2 in PC12 cells cotransfected with the HA-Syt IV CD and 
PC2. To do this, the doubly transfected cells and PC12/PC2 
cells were FACS-sorted using anti-HA and anti-PC2 antibodies. 
In the doubly transfected cells expressing HA-Syt IV, there was 
a higher ratio of pro-PC2 to PC2 than in PC12/PC2 cells (Fig. 9 C). 
The processing defect of pro-PC2 is not a result of its failure to 
enter granules because in the doubly transfected cells PC2 colo-
calized with the MSG marker chromogranin B (CgB; Fig. 9 D). 
Furthermore, when PC12 cells expressing the HA-Syt IV CD 
were examined by EM after immunolabeling with an anti-HA 
antibody, compared with wild-type cells, the Golgi was not 
fragmented and secretory granule formation was not perturbed 
in these cells (unpublished data).
Discussion
In this study, we used a specifi  c anti–Syt IV antibody (Ibata et al., 
2000) and subcellular fractionation approaches in   undifferentiated 
Figure 8.  Syt IV depletion inhibits SgII processing in 
PC12/PC2 cells. (A) Syt IV siRNA– or mock-transfected 
PC12/PC2 cells were pulse-labeled with [
35S]sulfate for 
5 min and chased for the indicated length of time. Cells 
were lysed in TNTE and a heat-stable fraction was prepared 
and analyzed by SDS-PAGE gel and autoradiography. 
  Arrowheads indicate the position of the SgII-processing 
products p38 and p18. (bottom) The same gel presented 
in the top image, but at higher exposure. (B) Quantiﬁ  ca-
tion of the ratio of p38 and p86 using ImageJ. Three sepa-
rate experiments were analyzed and the average is shown. 
Error bars are the SEM. P < 0.02, paired t test.JCB • VOLUME 173 • NUMBER 2 • 2006  248
PC12 cells to demonstrate that Syt IV is found on ISGs and is 
absent from MSGs, confi  rming and extending previous studies 
(Eaton et al., 2000; Fukuda et al., 2003). The CD of Syt IV in-
hibited in vitro ISG homotypic fusion, suggesting that Syt IV is 
involved in secretory granule maturation. siRNA depletion dem-
onstrated that Syt IV is required for ISG–ISG fusion in vivo. 
A previous study has shown that microinjection of recombinant 
Syt IV in endocrine β cells did not effect calcium-evoked insulin 
secretion (Gut et al., 2001). Similarly, catecholamine release 
from “cracked” PC12 cells was not changed by the addition of 
recombinant Syt IV (Tucker et al., 2003). Collectively, these 
data suggest that the ISG-localized Syt IV is not a regulator of 
calcium-triggered exocytosis in undifferentiated PC12 cells, but, 
rather, is involved in regulating ISG–ISG membrane fusion.
Interestingly, we found that the MSG-localized isoforms 
Syt I, IX, and VII did not have any effect on the regulation of 
ISG–ISG fusion. Our data are in agreement with studies showing 
that Syt IV displays a different distribution to Syt I, VII, and IX in 
PC12 cells (Ibata et al., 2000; Fukuda, 2004). Moreover, Syt IV 
lacks the ability to heterooligomerize with Syt I   (Osborne et al., 
1999; Fukuda and Mikoshiba, 2000) and does not   copurify with 
Syt IX (Fukuda, 2004). Similarly, Syt VII was found to form 
complexes with Syt I and IX, but not with Syt IV (Fukuda et al., 
2004; Wang et al., 2005). Syt I, VII, and IX were shown to be 
involved in calcium-regulated exocytosis in PC12 cells, leading 
to the idea that these isoforms regulate different membrane fu-
sion events from those involving Syt IV.
The in vitro binding assay showed that the Syt IV CD is 
recruited to ISG membranes, which suggests that the site of in-
hibition is on these membranes. Syt IV CD bound specifi  cally 
to ISGs and this binding is strictly via protein components, as 
the recruitment was completely inhibited after the pretreatment 
of ISG membranes with trypsin. Our experiments also confi  rm 
the data showing that Syt IV, in contrast to Syt I, is not a 
  phospholipid-binding isoform (Dai et al., 2004). The proposal 
that the Syt IV CD functions on the membrane concurs with 
data on the mode of inhibition of the Syt I CD in vesicle fusion 
with the plasma membrane (Earles et al., 2001; Zhang et al., 
2002), where the association of the added Syt I CD with Stx1 
and SNAP-25 inhibited the assembly of the endogenous Syt I–
SNARE complexes. In the same way, the CD of Syt IV might 
bind to ISG SNAREs, thereby inhibiting the formation of an 
endogenous Syt IV–ISG SNARE complex, leading to inhibition 
of ISG–ISG fusion.
The recruitment of the Syt IV CD to ISG membranes, as 
well as its inhibitory effect on fusion, led us to ask if Syt IV 
and Stx6 colocalize and interact. Immunostaining of PC12 
cells with anti-Stx6 and anti–Syt IV antibodies showed colo-
calization mainly in the juxtanuclear area, which is unlikely to 
be endosomes because, unlike Stx6 (Bock et al., 1997), Syt IV 
is not found on endosomes (Fukuda and Yamamoto, 2004). 
The immunoprecipitation of endogenous Syt IV with Stx6, 
and direct binding of the recombinant proteins to each other in 
vitro, suggested that these two proteins are in the same com-
plex and could be regulating the same fusion event. We found 
that both Syt IV-C2A and C2B domains bind Stx6, and that 
they most likely cooperate to bind to Stx6. Syt I was also found 
to bind to SNAP-25 and Stx1 through its C2A and C2B 
  domains (Chapman et al., 1996; Gerona et al., 2000), and 
both domains are thought to cooperate to regulate fusion 
Figure 9.  Syt IV CD inhibits PC2 maturation and PC2-dependent SgII 
  processing. (A) PC12 cells were cotransfected with HA-Syt IV CD and PC2, 
HA-Syt I CD and PC2, or PC2 alone. The cells were ﬁ  xed and labeled with 
rat anti-HA (green), rabbit anti-PC2 (blue), and mouse anti-p18 (red). 
(B) Transfected cells were individually selected and the mean of intensity 
of each channel was measured. Columns represent average of the mean of 
intensity of each channel. Error is the SEM, where n = 22 cells for all con-
ditions. (C) PC12 cells were cotransfected with HA-Syt IV CD and PC2. 
Cells positive for both HA-Syt IV and PC2 were FACS-sorted by labeling 
with anti-HA antibody (Alexa Fluor 488) and anti-PC2 antibody (Alexa 
Fluor 647). As a control, PC12/PC2 cells labeled for PC2 were FACS-
sorted using identical conditions. 150,000 HA-Syt IV
+/PC2
+ cells and 
300,000 PC12/PC2 cells were loaded on an SDS-PAGE gel and immuno-
blotted with the anti-PC2 antibody. 5 μg of a PC12 cell lysate was used 
as a negative control for the PC2 antibody. (D) PC12 cells cotransfected 
with HA-Syt IV CD and PC2 were ﬁ  xed and labeled with anti-HA, anti-PC2, 
and chromogranin B (CgB) antibodies. Bars, 5 μm.SYT IV REGULATES ISG MATURATION • AHRAS ET AL. 249
  (Earles et  al., 2001). It would be interesting to investigate 
whether an individual domain or both domains are required for 
ISG homotypic fusion. Unfortunately, because of the insolu-
bility of the GST-C2A and C2B domains, we could not inves-
tigate whether individual domains have an inhibitory effect. 
It is unlikely that the formation of a Syt IV–Stx1–SNAP-25 
complex (Wang et al., 2003; Rickman et al., 2004) is involved 
in ISG fusion, as ISG fusion is not sensitive to the addition of 
botulinum neurotoxins (Wendler et al., 2001).
 To understand the mechanism by which Syt IV is regu-
lating ISG homotypic fusion, and, more specifi  cally, whether 
inhibition with the Syt IV CD is synergistic with the inhibition 
by Stx6 antibodies, we added both reagents to the fusion assay, 
which resulted in an additive inhibition of ISG–ISG fusion. 
One explanation for this result is that the fusion-competent 
ISGs are at different stages when isolated, and, therefore, some 
of the ISGs will be past the stage blocked by one or the other 
reagent. Our results support the notion that Syt IV and Stx6 
function at different stages, rather than synergistically at the 
same stage of ISG–ISG fusion. We found that the binding of 
Syt IV CD to ISG membranes was not inhibited by the addition 
of anti-Stx6 antibody (and vice versa; unpublished data). This 
result suggests that the Syt IV–binding site in Stx6 is different 
from the epitope for the anti-Stx6 antibody. Our data cannot ex-
clude the possibility that Syt IV and Stx6, although in the same 
complex, could function at different steps during tethering, 
docking, and fusion of ISGs.
Most importantly, we were able to demonstrate a role for 
Syt IV in the maturation of ISGs in vivo. First, using siRNA 
  depletion of Syt IV we found that Syt IV was required for ISG 
fusion and for effi  cient processing of newly synthesized SgII by 
PC2. Second, the dominant-negative Syt IV CD inhibited SgII 
processing by exogenous PC2 in PC12 cells. The greatest 
  reduction in processing occurred when the processing rate was 
maximal in untreated controls at 45–60 min. This correlates 
with the t1/2 of 45 min for fusion and maturation of ISGs in 
PC12 cells. Recently, Kuliawat et al. (2004) showed that ex-
pression of a soluble form of Stx6 in INS-1 β cells slowed 
  proinsulin processing and concluded that this reduction in pro-
cessing was caused by an indirect effect on biosynthetic traffi  c. 
The inhibition of SgII processing that we observe is probably a 
direct result of an inability to activate PC2 in the maturing ISGs 
because PC2 was found mainly in the unprocessed proform 
in cells transfected with the dominant-negative Syt IV CD. 
We have been unable to test PC2 activation after siRNA treat-
ment because of a lower than usual transfection effi  ciency after 
siRNA treatment, which precludes expressing PC2 in the Syt IV–
defi   cient PC12 cells. As PC2 autocatalytic activation is 
  dependent on acidifi  cation of the granules (Lamango et al., 
1999), which occurs during the maturation from ISGs to MSGs, 
we speculate that the reduction in pro-PC2 processing could be 
caused by a failure to acidify the ISGs. Although the mecha-
nism of secretory granule acidifi  cation is not known, it has been 
proposed to occur after an increase in the density of the vacuolar 
H
+-ATPase, as well as a decrease in the H
+ permeability (Wu 
et al., 2001). Perturbation of the vacuolar H
+-ATPase has also 
been shown to reduce processing in Xenopus laevis  intermediate 
pituitary cells (Schoonderwoert et al., 2000). We propose that 
the Syt IV CD, through an inhibition of homotypic fusion, 
which may also limit membrane remodeling, may inhibit acidi-
fi  cation. Further biochemical and morphological analyses will 
be used to study the regulation of the secretory granule pH in 
vitro, and should provide further information on how secretory 
granule biogenesis occurs.
Materials and methods
Cells and reagents
PC12 cells (clone 251) and PC12/PC2 cells stably expressing PC2 were 
described previously (Dittie and Tooze, 1995). HEK293A cells were 
  purchased from Invitrogen, BAPTA was obtained from Calbiochem, and 
[
35S]sulfate was purchased from GE Healthcare. All other reagents were 
obtained from Sigma-Aldrich.
Antibodies
Polyclonal anti–Syt IV antibody was a gift from M. Fukuda (Institute of Physi-
cal and Chemical Research Institute, Saitama, Japan). Monoclonal anti-
p18 and polyclonal anti-Stx6 antibody were previously described (Dittie 
and Tooze, 1995; Wendler et al., 2001). Anti-PC2 antibody was a gift 
from B. Eipper (University of Connecticut, Farmington, CT). Monoclonal 
anti-Stx6 antibodies were purchased from BD Biosciences and Abcam PVC 
(3D10), and monoclonal anti–Syt I antibodies were obtained from Synaptic 
Systems GmbH. Mouse anti-HA and anti-myc antibodies were developed 
in-house (Cancer Research UK, London, UK). Rat anti-HA was obtained 
from Roche, and rabbit anti-myc was obtained from Abcam PVC.
Constructs and protein expression
GST-Syt I CD was obtained from G. Schiavo (Cancer Research UK). GST-
Syt VII and GST-Syt IX CDs were obtained from M. Fukuda. Rat Syt IV CD 
(aa 37–425), Syt IV-C2A domain (aa 150–261), and Syt IV-C2B domain 
(aa 281–245) were ampliﬁ  ed by RT-PCR from RNA extracted from PC12 
cells. GST-Syt IV CD was made by inserting the DNA into the SmaI–NotI 
sites of pGEX-2T expression vector, and the expressed proteins were puri-
ﬁ   ed using glutathione beads (GE Healthcare). To eliminate negatively 
charged bacterial contaminants, the GST fusion proteins were further puri-
ﬁ  ed on a size exclusion column, and then on a cation exchange column 
(Ubach et al., 2001). HA-Syt IV CD and HA-C2A and HA-C2B domains 
were inserted into pcDNA 3.1 (Invitrogen).
Labeling and subcellular fractionation of PC12 cells
PNS was prepared from [
35S]sulfate-labeled PC12 cells and then loaded 
successively on a continuous velocity gradient, followed by a discontinuous 
equilibrium sucrose gradient to separate ISGs and MSGs, as previously 
described (Tooze et al., 1991; Dittie et al., 1996).
In vitro ISG–ISG homotypic fusion and binding assays
ISG–ISG homotypic fusion was performed as previously described (Urbé 
et al., 1998). In brief, complete fusion reactions are comprised of the fol-
lowing: 100 μl [
35S]sulfate-labeled PNS from PC12 cells, 10 μl ISGs puriﬁ  ed 
from PC12/PC2 cells, an ATP-regenerating system and puriﬁ  ed recombi-
nant Syt IV, I, VII, or IX CDs, afﬁ  nity-puriﬁ  ed polyclonal anti-Stx6 antibody, 
or BAPTA as indicated in the ﬁ  gure legends. Fusion was carried out for 
30 min, followed by the processing reaction for 90 min at 37°C. The prod-
uct of PC2 cleavage of SgII, which is 
35S-labeled p18, was immunoprecipi-
tated and subjected to SDS-PAGE and autoradiography. The amount of 
p18 was quantiﬁ  ed using ImageJ (National Institutes of Health) analysis 
software. Binding assays were performed as previously described (Dittie 
et al., 1996). The amount of bound Syt IV or I CDs was detected using 
anti–Syt IV and anti–Syt I antibodies, and was quantiﬁ  ed using ImageJ 
analysis software.
Transfections, indirect immunoﬂ  uorescence, and FACS sorting 
of PC12 cells
PC12 cells were seeded on poly-D-lysine–coated coverslips and transfected 
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
  instructions. Cells were ﬁ  xed 24 h after transfection with 3% paraformalde-
hyde, permeabilized with 0.2% Triton X-100, and stained with the 
appropriate primary and secondary antibodies diluted in PBS with 0.2% 
gelatin. Images were acquired by confocal microscopy using a confocal JCB • VOLUME 173 • NUMBER 2 • 2006  250
microscope and software (LSM510; Carl Zeiss MicroImaging, Inc.). For the 
quantiﬁ  cation of p18 levels, confocal images were taken with identical 
  acquisition parameters and the mean of intensity of p18 was measured 
in individual cells using Photoshop 7.0 software (Adobe). To obtain a 
homogenous population of cells expressing both HA-Syt IV and PC2, or 
PC2 alone, FACS-sorting was used. Transfected cells were ﬁ  xed  and 
stained the same as the PC12 cells, and sorted using the Moﬂ  o FACS sorter 
(DakoCytomation). 150,000 HA/PC2-positive cells (starting from 2 × 10
8 
cells) and 300,000 PC2-positive cells were pelleted, lysed in sample 
  buffer, and subjected to SDS-PAGE analysis.
siRNA treatment, ISG–ISG fusion, and SgII processing
A SMARTpool of four siRNAs duplexes (Dharmacon) against rat Syt IV 
(1: 5′-G  A  A  G  A  A  A  G  C  A  U  U  U  G  U  G  G  U  G  -3′; 2: 5′-G  G  A  G  A  C  A  A  A  U  U  G  C  U  A  A  G-
U  G  -3′; 3: 5′-C  A  A  C  A  A  G  A  C  U  C  C  U  C  C  A  U  A  C  -3′; and 4: 5′-U  A  A  A  G  G  A  G  U-
U  G  A  U  A  U  C  U  A  C  -3′) was used at a ﬁ  nal concentration of 50 nM. Duplex 3 
gave comparable results when used alone. Transfection of siRNAs in PC12 
cells was performed using Dharmafect 2 (Dharmacon) in DME-containing 
full serum without antibiotics for 24 h, followed by a second treatment 24 h 
later. 3 d after transfection, cells were either ﬁ  xed for immunoﬂ  uorescence, 
lysed in sample buffer, or subjected to pulse-chase labeling.
To monitor SgII processing, PC12/PC2 cells were used. To control 
for sorting and budding from the TGN, PC12 cells were used. Pulse-chase 
[
35S]sulfate-labeling of PC12 cells and analysis of SgII were performed as 
previously described (Urbé et al., 1997).
GST pull-down experiments and coimmunoprecipitation
GST or GST-Syt IV CD bound to glutathione beads was incubated with 
  Triton X-100–solubilized lysates from myc-Stx6–transfected HEK293 cells 
in binding buffer (25 mM Hepes-KOH, pH 7.2, 25 mM MgOAc, and 
0.5% Triton X-100). Proteins bound to beads, and 10% of the input were 
subjected to SDS-PAGE and immunoblotting with anti-myc antibodies.
For immunoprecipitation, HEK293 cells were transfected as 
  described above, lysed in TNTE buffer (20 mM Tris, pH 7.5, 150 mM 
NaCl, 0.3% Triton X-100, and 5 mM EDTA), and incubated with anti-HA, 
anti-Myc coupled to protein G Sepharose beads (GE Healthcare), or with 
beads alone. For coimmunoprecipitation of endogenous Syt IV with Stx6, 
TNTE lysates from PC12 cells were incubated with monoclonal anti-Stx6 
antibody (Abcam PVC) and protein G beads. Immunoprecipitates were an-
alyzed by SDS-PAGE, followed by immunoblotting with anti-HA, anti-myc, 
or anti–Syt IV antibody.
Online supplemental material
Fig. S1 shows by indirect immunoﬂ  uorescence that Syt IV colocalizes with 
Stx6, but not with p18, in PC12/PC2 cells. Fig. S2 shows that BAPTA 
inhibits ISG homotypic fusion. Fig. S3 shows that Golgi morphology 
and secretory granule biogenesis are normal in cells treated with Syt 
IV-siRNA. Online supplemental material is available at http://www.jcb.
org/cgi/content/full/jcb.200506163/DC1.
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